2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 208-210
This program is top science that showcases hot topics in platelet and megakaryocyte biology. It is balanced between both platelets and megakaryocytes and also a a broad array of topics. Male to Female representation was difficult, but we currently have one woman. Our first alternate is a woman and we suggest having woman moderators (we suggested two junior and two more senior).<br /><br />abs26-7483 was not chosen for an oral presentation due to concerns about lack of key information in the abstract that didn't allow the group to discern the impact of the findings.<br /><br />Backups<br />1. abs26-10358<br />2. abs26-13313<br />3. abs26-1646
Technology and Procedures, Assays, Biological Processes, Pathogenesis, Hematopoiesis, Metabolism, Molecular Biology, Diseases, Bleeding and Clotting, Thrombocytopenias, Infectious Diseases, Bacterial, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MDS, Study Population, Human, Animal Model
PAPER

469 Engineered biomimetic platelet membrane-coated nanoparticles reduce pathogen-driven thromboinflammation in bacterial sepsis

Anh T. P. Ngo, PhD, Carly Carbery2, Hasti Vatan Navaz3, Samira Dahesh4, Elisabet Bjånes5, Shawn Hannah6, Megan O'hara7, Kalisa Kang8, Hervé Besançon9, Dzung Le10, Lei Sun11, Weiwei Gao12, Liangfang Zhang13, Victor Nizet, MD14
1 University of California San Diego, La Jolla, United States
2 University of California San Diego, La Jolla, United States
3 University of California San Diego, La Jolla, United States
4 University of California San Diego, La Jolla, United States
5 University of California San Diego, La Jolla, United States
6 University of California San Diego, La Jolla, United States
7 University of California San Diego, La Jolla, United States
8 University of California San Diego, La Jolla, United States
9 University of California San Diego, La Jolla, United States
10 University of California San Diego, La Jolla, United States
11 University of California San Diego, La Jolla, United States
12 University of California San Diego, La Jolla, United States
13 University of California San Diego, La Jolla, United States
14 University of California San Diego, La Jolla, United States
Introduction: Platelets play crucial roles in hemostasis and innate immune defense. We previously engineered biomimetic platelet membrane-coated nanoparticles (PNP) that protect against murine methicillin-resistant Staphylococcus aureus (MRSA) sepsis by neutralizing pore-forming toxins. Here, we investigated whether PNP also reduce pathogen-driven thromboinflammation and consumptive coagulopathy while preserving antimicrobial platelet function. 

Methods: Platelet membrane was derived by freeze-thawing. Poly(lactic-co-glycolic acid) core, prepared by acetone/water nanoprecipitation, was added to platelet membrane and sonicated to create PNP that retain surface characteristics of platelets.

Effects of PNP on platelet aggregation in response to adenosine diphosphate (ADP), arachidonic acid (AA), thrombin, and a toxin were assessed by light transmission aggregometry. To assess PNP effects on platelet killing of bacteria, platelets were infected with Pseudomonas aeruginosa (PA), Staphylococcus aureus (SA), or methicillin-resistant Staphylococcus aureus (MRSA) ± PNP for 1h at 37°C, followed by CFU enumeration.
 
Effects of PNP on biofilm formation were studied by incubating SA and MRSA with PNP in human plasma for 24h at 37°C, then stained with crystal violet, and quantified at 595nm. To determine whether PNP block coagulase-induced consumptive coagulopathy, blood was infected with vehicle or MRSA ± PNP for 3h at 37°C. Plasma was isolated and re-calcified to initiate fibrin formation, measured as change in turbidity at 405 nm.

PNP effects on coagulation were assessed by fibrin generation assay in plasma incubated with thrombin or lipopolysaccharide (LPS) ± PNP. To determine PNP effects on coagulation enzyme activity, factors (F) XIIa, XIa, and Xa were incubated with PNP for 30min at 4°C, followed by ultracentrifugation to pellet PNP. Residual enzyme activity was determined using enzyme-specific chromogenic substrates. To determine whether PNP protect FXIa from inhibition by protease nexin-II (PN-II), PNP-bound FXIa activity was measured after incubation with PN-II.

PNP effects on thrombosis were assessed by treating wildtype (WT) mice intravenously (i.v) with vehicle or PNP for 15min, followed by i.v thromboplastin infusion to induce systemic thrombosis. Blood and organs were harvested at 1min for hematological and histological analyses. Thrombin anti-thrombin (TAT) levels were measured by ELISA. PNP effects on sepsis-induced coagulopathy were studied by infecting WT mice i.v with PA, followed by immediate treatment with vehicle or PNP i.v. At 16h post infection, blood and organs were harvested for hematological and histological analyses and TAT ELISA. 

Results: PNP reduced platelet aggregation induced by ADP, AA, thrombin, and a toxin by 50%, while enhancing platelet killing of both Gram- (by 40%) and Gram+ bacteria (by 50%; eliminating SA and MRSA growth). PNP reduced SA and MRSA biofilm formation by 75%, and blocked MRSA-induced consumptive coagulopathy in whole blood, suggesting that PNP may protect platelets during infection by absorbing pro-coagulant proteins and bacterial toxins.

PNP interfered with thrombin- and LPS-induced plasma clotting, suggesting that PNP also interact with components of the coagulation cascade. We found that PNP selectively bound FXIIa and FXIa but not FXa. Unlike activated platelets, PNP did not enhance FXIIa and FXIa enzymatic activity or protect FXIa from inhibition by PN-II.

Murine thromboplastin infusion induced thrombocytopenia, leukopenia, and increased TAT levels, which were alleviated by PNP treatment. PA-infected mice treated with PNP exhibited reduced sepsis severity and lower plasma TAT levels, suggesting that PNP exerted antithrombotic effects that improved sepsis outcomes.

Conclusion: Our findings identify biomimetic platelet membrane-coated nanoparticles as a host-directed therapeutic strategy that selectively mitigates sepsis-associated thromboinflammation while preserving antimicrobial platelet function. Beyond their previously established role as toxin decoys, PNP retain selective regulatory properties of native platelet membranes that modulate intrinsic coagulation pathway activation, reduce consumptive coagulopathy, and limit systemic thrombosis during bacterial sepsis. These findings provide a strong rationale for further development of PNP as adjunctive therapies for bacterial sepsis and potentially other thromboinflammatory disorders.
Anh T. P. Ngo, PhD: No relevant conflicts of interest to declare.